The Richmond company (Nasdaq: BIOA) will get a fraction of the money upfront from Novartis (NYSE: NVS) — up to $20 million, ...

What Eli Lilly (NYSE: LLY) is doing is far more impressive. While many investors may buy it for its growth potential, here's ...

(Corrects paragraph 8 of Dec. 17 story to reflect that the EU regulator reversed its July decision in November to recommend ...

Eli Lilly’s recently announced plan to partner with digital health company Ro on its LillyDirect platform marks a new turning ...

Eli Lilly (NYSE:LLY) announced Wednesday that China's National Medical Products Administration (NMPA) has approved its ...

Pfizer’s financial challenges are offset by growth potential in oncology and strong dividends. Learn why PFE stock is a "Buy" ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...

But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose ...

The Village of Pleasant Prairie Plan Commission on Monday approved the preliminary site and operational plans for the ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...